U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C6H14O6S2
Molecular Weight 246.302
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUSULFAN

SMILES

CS(=O)(=O)OCCCCOS(C)(=O)=O

InChI

InChIKey=COVZYZSDYWQREU-UHFFFAOYSA-N
InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C6H14O6S2
Molecular Weight 246.302
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB01008 https://en.wikipedia.org/wiki/Busulfan

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic). Most common adverse reactions (incidence greater than 60%) were: myelosuppression, nausea, stomatitis, vomiting, anorexia, diarrhea, insomnia, fever, hypomagnesemia, abdominal pain, anxiety, headache, hyperglycemia and hypokalemia. Itraconazole and acetaminophen can decrease busulfan clearance. Phenytoin increases hepatic clearance of busulfan.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Busulfan is a small, highly lipophilic molecule that easily crosses the blood brain barrier.

Originator

Chester Beatty Research Institute
1
Sources: Lichtman M., 'Hematology: Landmark Papers of the Twentieth Century' (2000), P. 598. ISBN-13 | 978-0124485105

Approval Year

1954
119
Targets

Targets

Primary TargetPharmacologyConditionPotency
Crosslinking Agent
83
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
MYLERAN

Approved Use

BUSULFEX is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. BUSULFEX is an alkylating drug indicated for: •Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML) (1)

Launch Date

1954
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1222 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1167 μM × min
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.35 h
OTHER GOV
https://www.ema.europa.eu/en/documents/product-information/busilvex-epar-product-information_en.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
67.6%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
0.8 mg/kg 4 times / day steady-state, intravenous
dose: 0.8 mg/kg
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
BUSULFAN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
40 mg/m2 4 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 4 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
unhealthy, 1.2–17.2
Health Status: unhealthy
Age Group: 1.2–17.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
4 mg/kg 4 times / day multiple, oral
Overdose
Dose: 4 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Disc. AE: Seizures...
AEs leading to
discontinuation/dose reduction:
Seizures
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
18 mg/kg single, oral
Overdose
Dose: 18 mg/kg
Route: oral
Route: single
Dose: 18 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
unhealthy, 48
Health Status: unhealthy
Age Group: 48
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Disc. AE: Myelosuppression, Seizures...
AEs leading to
discontinuation/dose reduction:
Myelosuppression (severe)
Seizures
Venoocclusive disease
Fetal damage
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hepatotoxicity Disc. AE
40 mg/m2 4 times / day multiple, intravenous
MTD
Dose: 40 mg/m2, 4 times / day
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
unhealthy, 1.2–17.2
Health Status: unhealthy
Age Group: 1.2–17.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11025470
Seizures Disc. AE
4 mg/kg 4 times / day multiple, oral
Overdose
Dose: 4 mg/kg, 4 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
unhealthy, 14
Health Status: unhealthy
Age Group: 14
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15568037
Fetal damage Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Seizures Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Venoocclusive disease Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Myelosuppression severe
Disc. AE
0.8 mg/kg 4 times / day multiple, intravenous
Recommended
Dose: 0.8 mg/kg, 4 times / day
Route: intravenous
Route: multiple
Dose: 0.8 mg/kg, 4 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2C19
2057

CYP2E1
1060

BSEP
550

OATP1B1
1079

OATP1B3
961

MRP2
499

MRP3
246

MRP4
290
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no [IC50 >10 uM]
CYP2A6
911
 no [IC50 >10 uM]
CYP2C19
2141
 no [IC50 >10 uM]
CYP2C9
2497
 no [IC50 >10 uM]
CYP2D6
2546
 no [IC50 >10 uM]
CYP2E1
1146
 no [IC50 >10 uM]
BSEP
554
 no [IC50 >1000 uM]
MRP2
625
 no [IC50 >133 uM]
MRP3
326
 no [IC50 >133 uM]
MRP4
345
 no [IC50 >133 uM]
CYP3A4
2633
 no [IC50 >812 uM]
OATP1B1
1095
 yes
OATP1B3
970
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 likely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28901
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28901
ChemicalBook
CB2105891
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2105891
ChemicalBook
CB72673681
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB72673681
eMolecules
486878
https://www.emolecules.com/cgi-bin/more?vid=486878
MolPort
MolPort-001-783-406
https://www.molport.com/shop/molecule-link/MolPort-001-783-406
Selleck Chemicals
Busulfan(Busulfex)
http://www.selleckchem.com/products/Busulfan(Busulfex).html
ZINC
ZINC000001530572
http://zinc15.docking.org/substances/ZINC000001530572
PubMed

PubMed

TitleDatePubMed
A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.
2000 Nov
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
2000 Sep
Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation.
2001
Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
2001
Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
2001 Apr
Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation.
2001 Apr
Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation.
2001 Apr
Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans.
2001 Apr
Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.
2001 Apr
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
2001 Apr
Stability of busulfan in frozen plasma and whole blood samples.
2001 Apr
[Complications after high dose therapy and autologous stem cell transplantation. Retrospective study of an unselected patient sample].
2001 Apr 15
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
2001 Aug
The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro.
2001 Aug
Developing a pediatric outpatient transplantation program. The Children's Memorial Hospital experience.
2001 Aug 1
Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
2001 Feb
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.
2001 Feb
Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation.
2001 Feb
Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation.
2001 Feb
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
2001 Feb 1
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development.
2001 Feb 2
Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II).
2001 Jan
The biology and treatment of chronic myelogenous leukemia.
2001 Jan
Successful unrelated bone marrow transplantation for Shwachman-Diamond syndrome.
2001 Jan
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant.
2001 Jul
Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning.
2001 Jul
Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
2001 Jul
No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission.
2001 Jul 15
Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.
2001 Jul 15
Arsenic trioxide in the management of acute promyelocytic leukaemia.
2001 Jul-Aug
Congenital sideroblastic anaemia successfully treated using allogeneic stem cell transplantation.
2001 Jun
Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans.
2001 Jun
A single institutional experience with 43 pregnancies in essential thrombocythemia.
2001 Mar
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
2001 Mar
Accidental busulfan overdose: enhanced drug clearance with hemodialysis in a child with Wiskott-Aldrich syndrome.
2001 Mar
Pharmacokinetics of liposomal busulphan in man.
2001 Mar
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
2001 Mar
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
2001 Mar
Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation.
2001 Mar
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
2001 Mar 15
Synthesis and in vitro cytotoxicity of novel long chain busulphan analogues.
2001 Mar 26
Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
2001 May
High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
2001 May
O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells.
2001 May
Bizarre epithelial atypia of the sinonasal tract after chemotherapy.
2001 May
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
2001 Oct
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
2001 Oct
Monitoring of busulfan area under the curve: estimation by a single measurement.
2001 Oct
[Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
2001 Sep
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
2001 Sep
Patents

Patents

05994391
1
06107494
1
20010004454
41
JP2006502184A
41
JP2007525670A
150
JP2008533019A
34
JP2011525178A
25
JP2011528275A
456
JP2012500104A
108
JP4663232B2
15

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Oral administration: adult dose range for remission induction is 4 to 8 mg, total dose, daily. Dosing on a weight basis is the same for both pediatric patients and adults, approximately 60 mcg/kg of body weight or 1.8 mg/m2 of body surface, daily. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf456fc7-3a79-47f7-8acc-600b5e2f0dc2
0.8 mg per kg intravenously six hours for four consecutive days for a total of 16 doses
Route of Administration: Intravenous
In Vitro Use Guide
P39 myeloid cells were incubated with busulfan in concentrations ranging from 10 to 100 microg/ml for 2, 4 or 8 h, then washed and cultured in busulfan-free medium for 72 h.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:50:41 GMT 2025
Edited
by admin
on Mon Mar 31 17:50:41 GMT 2025
Record UNII
G1LN9045DK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUSULFAN
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
1,4-BUTANEDIYL DIMETHANESULFONATE
Preferred Name English
BUSULFANUM [WHO-IP LATIN]
Common Name English
BUSULFAN [MI]
Common Name English
BUSULFAN [JAN]
Common Name English
BUSULFAN [EMA EPAR]
Common Name English
BUSILVEX
Brand Name English
BUSULFAN [USP MONOGRAPH]
Common Name English
BUSULFAN [MART.]
Common Name English
BUSULFAN [IARC]
Common Name English
BUSULFAN [VANDF]
Common Name English
1,4-BUTANEDIOL DIMETHANESULPHONATE
Systematic Name English
TETRAMETHYLENE DI(METHANESULFONATE)
Systematic Name English
BUSULFAN [HSDB]
Common Name English
LEUCOSULFAN
Common Name English
SULPHABUTIN
Common Name English
BUSULFAN [EP IMPURITY]
Common Name English
1,4-BUTANEDIOL, DIMETHANESULFONATE
Systematic Name English
Busulfan [WHO-DD]
Common Name English
1,4-Butanediol dimethanesulfonate
Systematic Name English
BUSULPHAN
Systematic Name English
BUSULFEX
Brand Name English
BUSULFAN FRESENIUS KABI
Brand Name English
NSC-750
Code English
NCI-C01592
Code English
BUSULFAN [ORANGE BOOK]
Common Name English
busulfan [INN]
Common Name English
MYELOSANUM [WHO-IP]
Common Name English
1,4-BUTANEDIOL, DIMETHANESULPHONATE
Systematic Name English
BUSULFAN [EP MONOGRAPH]
Common Name English
BUSULFAN [WHO-IP]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS BUSULFAN FRESENIUS KABI (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 140700
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 394513
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
NDF-RT N0000000236
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 160402
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 81694
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
LIVERTOX NBK548886
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 161602
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
NDF-RT N0000175558
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
EU-Orphan Drug EU/3/00/011
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
WHO-VATC QL01AB01
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 105897
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
EMA ASSESSMENT REPORTS BUSILVEX (AUTHORIZED: HEMATOPOIETIC STEM CELL TRANSPLANTATION)
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
FDA ORPHAN DRUG 83094
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
WHO-ATC L01AB01
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
IARC Busulfan
NCI_THESAURUS C222
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
Code System Code Type Description
MESH
D002066
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
EVMPD
SUB05993MIG
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ALANWOOD
busulfan
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
WIKIPEDIA
BUSULFAN
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
RXCUI
1828
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB01008
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
BUSULFAN
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY Description: A white, crystalline powder. Solubility: Very slightly soluble in water; sparingly soluble in acetone R; slightly soluble in ethanol (~750 g/l) TS. Category: Cytotoxic drug. Storage: Busulfan should be kept in a well-closed container, protected from light. Additional information: CAUTION: Busulfan must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Busulfan contains not less than 98.5% and not more than 100.5% of C6H14O6S2, calculated with reference to the dried substance.
CAS
55-98-1
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
SMS_ID
100000085245
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
IUPHAR
7136
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
DRUG CENTRAL
438
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
PUBCHEM
2478
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
NCI_THESAURUS
C321
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
HSDB
7605
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
FDA UNII
G1LN9045DK
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
LACTMED
Busulfan
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
DAILYMED
G1LN9045DK
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
CHEBI
28901
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
MERCK INDEX
m2778
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY Merck Index
NSC
750
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-250-2
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
INN
564
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
EPA CompTox
DTXSID3020910
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
ChEMBL
CHEMBL820
Created by admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of BUSULFAN
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.63.pdf
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966